ArticleInternational journal of chronic obstructive pulmonary disease2025
Hypercholesterolemia as a Causal Risk Factor for COPD: Biomarker Discovery and Therapeutic Implications From NHANES Data.
Article in International journal of chronic obstructive pulmonary disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic obstructive pulmonary disease (COPD), the third leading cause of global mortality, imposes substantial socioeconomic burdens. Existing therapies, such as smoking cessation and non-invasive ventilation, primarily alleviate symptoms without arresting disease progression. Comorbidities, including cardiovascular disease and metabolic syndrome, exacerbate functional decline, yet the causal role of dyslipidemia in COPD pathogenesis remains unclear. This study seeks to establish a causal link between hypercholesterolemia and COPD while identifying potential biomarkers and therapeutic targets. Methods: Leveraging cross-sectional data from the National Health and Nutrition Examination Survey (NHANES), we employed Mendelian randomization (MR) analysis using 71 single-nucleotide polymorphisms (SNPs) associated with hypercholesterolemia, integrated with bioinformatics tools for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. Demographic variables (age, sex, body mass index [BMI]) and dietary factors were compared between COPD patients and controls. Results: Univariate analyses identified significant differences in demographics and dietary patterns between COPD and non-COPD groups (P < 0.05). Multivariate logistic regression revealed: (1) a reduced risk of COPD with elevated total cholesterol levels (odds ratio [OR]: 0.815, 95% confidence interval [CI]: 0.721-0.923, P = 0.001); and (2) increased COPD risk associated with higher age and BMI. Bioinformatics analyses pinpointed atorvastatin, fenofibrate, and pravastatin as candidate therapeutics. Gene interaction networks and pathway enrichment highlighted roles for lipid homeostasis and cholesterol metabolism. Conclusion: Analysis of NHANES data demonstrates an inverse association between cholesterol levels and COPD prevalence, with MR confirming a causal relationship. These findings underscore targetable pathways and suggest repurposing statins and fibrates, meriting further mechanistic studies and clinical trials for validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.